Home
Billing codes
15792

PAYER POLICY CHANGES

15792 Insurance Policy Changes

CPT 15792, in plain terms, covers A chemical treatment applied to non-facial skin to remove the outer layer and improve appearance. CPT 15792 is referenced in 13 tracked payer policy changes from Excellus BlueCross BlueShield, Independence Blue Cross, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 15792 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Official descriptor: CPT 15792 on AAPC

Excellus BlueCross BlueShield · Effective Sep 17, 2026Medium impact
Cosmetic and Reconstructive Procedures 7.01.11
Policy 7.01.11 treats reconstructive procedures as medically appropriate only when a functional deficit is documented, a reconstructive purpose is documented, and the indication-specific criteria are met, such as the criteria for acne surgery, benign skin lesion removal, breast procedures, pectus repair, dermabrasion, otoplasty, hypertrophic scar revision, and vulvectomy as part of cancer surgery. Procedures that reshape structures to improve appearance or self-esteem without a functional deficit, including breast augmentation with implants, breast lift, rhytidectomy, tattooing, chemical peels, hair transplant, hair removal, and non-surgical body sculpting, are considered cosmetic and not medically necessary for all indications unless the reconstructive criteria are met. Cryotherapy for acne, certain hyperhidrosis treatments, and autologous melanocyte transplantation for vitiligo are investigational.
Independence Blue Cross · Effective Dec 29, 2025Medium impact
MA11.103c, Chemical Peels
Independence Blue Cross Medicare Advantage reissued MA11.103c to clarify that chemical peels for actinic keratoses are now covered WITHOUT restrictions based on lesion count or patient characteristics. The policy also removed ICD-10 diagnosis code L57.9 and maintains coverage criteria for dermal peels treating other premalignant lesions (requiring >10 lesions and failed topical therapy), while epidermal peels for non-actinic keratosis premalignant lesions remain non-covered.
Independence Blue Cross · Effective Dec 29, 2025Medium impact
MA11.103c, Chemical Peels
Independence Blue Cross Medicare Advantage has expanded coverage for chemical peels treating actinic keratoses to be medically necessary without restrictions, effective 12/29/2025. Additionally, the ICD-10 code L57.9 has been removed from the policy. Billing teams must update systems to reflect unrestricted coverage for actinic keratosis treatment and ensure proper documentation is submitted with all chemical peel claims.
Aetna · Identified Oct 3, 2026Medium impact
Rosacea (CPB 0547, reviewed 2026-08-21)
Aetna's Clinical Policy Bulletin 0547 considers medical treatment of rosacea medically necessary, but surgical treatment of disfigurement from rosacea, such as scarring and telangiectasias, is considered cosmetic. Excision or shaving of rhinophyma is medically necessary only for bleeding or infection refractory to medical therapy, such as the need for repeated cautery of bleeding telangiectasias or frequent courses of antibiotics for pustular eruptions. Intense pulsed light for ocular rosacea, photodynamic therapy, platelet-rich plasma injection, and several rosacea biomarker and imaging tests are listed as experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Rosacea (CPB 0547, reviewed 2025-08-22)
Aetna considers medical treatment of rosacea medically necessary. Surgical treatment of disfigurement from rosacea, such as scarring and telangiectasias, is considered cosmetic, and cosmetic surgery is excluded from coverage under Aetna standard benefit plans. Aetna considers excision or shaving of rhinophyma medically necessary for bleeding or infection refractory to medical therapy, and considers intense pulsed light for ocular rosacea, photodynamic therapy, and platelet-rich plasma injection experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Dermabrasion, Chemical Peels, and Acne Surgery (CPB 0251, reviewed 2026-04-15)
Aetna considers dermabrasion for superficial basal cell carcinomas and pre-cancerous actinic keratoses, medium and deep chemical peels for actinic keratoses when there are 15 or more lesions, and specified acne surgery procedures medically necessary when criteria are met. Dermabrasion for active acne, diffuse silicone granuloma, dyschromias, keloids, melasma and vitiligo, chemical peels for active acne, and fractional radiofrequency and micro-needling for acne scars and other listed indications are considered experimental, investigational, or unproven. Dermabrasion for scar revision and removal of acne scars, and chemical peels for acne scarring, melasma, and skin wrinkling or lentigines, are considered cosmetic.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Non-Pharmacologic Treatment of Rosacea
Non-pharmacologic treatment of rosacea, including laser and light therapy, dermabrasion, chemical peels, surgical debulking, and electrosurgery, is considered investigational under this policy. The policy's investigational code table includes dermabrasion codes 15780, 15781, 15782 and 15783, chemical peel codes 15788, 15789, 15792 and 15793, and destruction codes for cutaneous vascular proliferative lesions 17106, 17107 and 17108.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Chemical Peels
Epidermal chemical peels used to treat photo-aged skin, wrinkles, or acne scarring are considered cosmetic, and dermal chemical peels used as a treatment of end-stage acne scarring are considered cosmetic. Dermal chemical peels used to treat individuals with more than 10 actinic keratoses or other premalignant skin lesions, where treating each lesion becomes impractical, may be considered medically necessary. Epidermal chemical peels used to treat individuals with active acne that has failed a trial of topical and/or oral antibiotic therapy are considered medically necessary, using superficial peels with 40%-70% alpha hydroxy acids as comedolytic therapy.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.109a, Procedures for the Treatment of Acne
This is a reissue of Independence Blue Cross Medicare Advantage Policy MA11.109a confirming the Company's continuing position that laser therapy, electrosurgery, cryosurgery, and chemosurgery for treatment of active acne are NOT covered (experimental/investigational), and services for acne scarring are NOT covered (cosmetic). No substantive policy changes have been made; this is a routine review and reissue.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.109a, Procedures for the Treatment of Acne
Independence Blue Cross has reissued MA11.109a to reaffirm that laser therapy, electrosurgery, cryosurgery, and chemosurgery (chemical peels) for treating active acne vulgaris remain non-covered as experimental/investigational procedures under Medicare Advantage plans. These same procedures for acne scarring remain non-covered as cosmetic services. This is a reaffirmation of the Company's continuing position with no substantive changes to coverage criteria.
Independence Blue Cross · Identified Jun 19, 2026Low impact
11.08.29e, Procedures for the Treatment of Acne
Independence Blue Cross has reissued Policy 11.08.29e confirming that laser therapy, electrosurgery, cryosurgery, and chemosurgery (chemical peels) for treating active acne remain classified as experimental/investigational and are not covered. Additionally, these same procedures for acne scarring are classified as cosmetic and are not covered for most plans. No coverage policy changes have been made; this is a reaffirmation of the existing non-coverage position.
Independence Blue Cross · Identified Jun 19, 2026Low impact
11.08.08h, Chemical Peels
Independence Blue Cross has reissued policy 11.08.08h on chemical peels with no substantive coverage changes. The policy maintains that dermal chemical peels (CPT 15789, 15793) for actinic keratoses and premalignant skin lesions are medically necessary only when more than 10 lesions are present AND topical 5-FU or imiquimod has failed or is contraindicated. Epidermal chemical peels (CPT 15788, 15792) remain not covered for these conditions, and all cosmetic peels are excluded.
Independence Blue Cross · Identified Jun 19, 2026Low impact
11.08.29e, Procedures for the Treatment of Acne
This is a reissue of Independence Blue Cross policy 11.08.29e with no substantive changes to coverage. The policy continues to classify laser therapy, electrosurgery, cryosurgery, and chemosurgery (including chemical peels) for active acne treatment as experimental/investigational and not covered, and for acne scarring as cosmetic and not covered. Billing teams should continue denying claims for these procedures under this policy.

Watch 15792

Get one email when a payer policy names 15792, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules17

Payers requiring prior auth17

Aetna · Effective November 1, 2026
Prior authorization required
Participating provider precertification list for Aetna
Anthem BCBS · Effective November 1, 2026
Prior authorization required
Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial)
Fidelis Care · Effective November 1, 2026
Prior authorization required in some cases
Fidelis Care Metal-Level Products authorization grid

FREQUENTLY ASKED QUESTIONS

Does Aetna require prior authorization for 15792?

Aetna lists 15792 on Participating provider precertification list for Aetna for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Ambetter require prior authorization for 15792?

Ambetter lists 15792 on Ambetter from Arizona Complete Health CMS-0057-F prior authorization requirements for exchange plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does AmeriHealth Caritas require prior authorization for 15792?

AmeriHealth Caritas lists 15792 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Anthem BCBS require prior authorization for 15792?

Anthem BCBS lists 15792 on Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial) for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Arizona Complete Health require prior authorization for 15792?

Arizona Complete Health lists 15792 on Arizona Complete Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect CPT 15792?

There are 13 tracked policy changes affecting CPT 15792, including updates from Excellus BlueCross BlueShield, Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 15792?

Payers that have issued tracked updates for CPT 15792 include: Excellus BlueCross BlueShield, Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 15792 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 15792. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 15792?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for 15792

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 15792 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Cosmetic and Reconstructive Procedures 7.01.11

MA11.103c, Chemical Peels

MA11.103c, Chemical Peels

Rosacea (CPB 0547, reviewed 2026-08-21)

Rosacea (CPB 0547, reviewed 2025-08-22)

Dermabrasion, Chemical Peels, and Acne Surgery (CPB 0251, reviewed 2026-04-15)

Non-Pharmacologic Treatment of Rosacea

Chemical Peels

MA11.109a, Procedures for the Treatment of Acne